NeoStrata launches Psorent psoriasis topical treatment

Psorent contains LCD (liquid carbonis distillate), which has shown efficacy against psoriasis symptoms in a novel, aesthetically advanced formulation and package that promotes high patient compliance. Psorent will be available without a prescription from dermatologists beginning March 2008.

Barbara Green, vice president for technology and clinical affairs at NeoStrata, said: “With the launch of Psorent, physicians will be able to offer patients a novel psoriasis treatment that reduces the unpleasant aspects of traditional coal tar therapy, resulting in high patient compliance without compromising efficacy or safety. Psorent’s effective and unique fast-absorbing solution applies easily and conveniently making it an ideal first-line therapy for the vast majority of psoriasis patients.”